Pharmaceutical Contract Development Market Expectations and Growth Trends Highlighted Until 2026

The Global Pharmaceutical Contract Development Market in terms of revenue is expected to be worth $171.3 billion by 2026, growing at a CAGR of 7.3% in the upcoming years.

The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is driven mainly by factors such as rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs. The increasing demand for biological therapies, the growing focus on specialty medicines, growth in the nuclear medicine sector, and advancements in cell and gene therapies are also expected to offer market growth opportunities in the coming years.

Download PDF Brochure:

Browse in-depth TOC on “Pharmaceutical Contract Development Market”

284 – Tables

39 – Figures

253 – Pages

Key Market Players

The global pharmaceutical contract development and manufacturing market is highly consolidated. Key players in the pharmaceutical contract development and manufacturing market include Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group Ltd. (Switzerland), Recipharm AB (Sweden), AbbVie Inc. (US), Aenova Group (Germany), Almac Group (UK), Siegfried Holding AG (Switzerland). Acquisitions and product launches are the key growth strategies undertaken by these companies to maintain their positions in the market.

Pharmaceutical Contract Manufacturing Market Dynamics

Drivers: Patent expiry and increasing demand for generic drugs

Generics are cost-effective drugs with therapeutic effectiveness and safety profiles that are similar to their branded counterparts. One of the major factors driving the growth of the generics market is the increasing pressure to reduce rising healthcare costs. Considering such cost benefits, governments across various countries are promoting the use of generic drugs.

Another major factor driving the growth of the generics market is the expiration of several drugs & patents. In developing countries such as South Korea, around 62 patents covering 158 pharmaceutical products are scheduled to expire in 2021. Although generic erosion because of the patent cliff has resulted in significant revenue and volume losses for the branded drug industry, patent expiration enables the entry of several cheaper generic counterparts in the market (which will boost the volume of drugs sold). This is a positive indicator of market growth, as generics companies outsource around 80% of their production to CDMOs.

Request Sample Pages:

Opportunities: Growing demand for cell and gene therapies

Given the personalised nature of cell and gene therapies, they are highly specific and hold the potential to address unmet medical needs associated with treating several disorders. Their promising therapeutic potential has led many pharmaceutical companies and investors to put a significant amount of capital towards developing and commercialising these therapies. As of February 2020, nine cell and gene therapies have been approved by the US FDA. In 2020, around 362 cell and gene therapies were under clinical development. The growing number of cell therapy candidates, coupled with their rapid progression through the various phases of clinical development and their complex manufacturing process, increases the demand for facilities that offer manufacturing services for these therapies.

The pharmaceutical contract manufacturing market was dominated by large pharmaceutical companies.

Based on end users, the market is segmented into big pharmaceutical companies, small and medium-sized pharmaceutical companies, generic pharmaceutical companies, and other end users. In 2020, big pharmaceutical companies accounted for the largest share of the pharmaceutical contract development and manufacturing market, and this trend is expected to continue during the forecast period. The large share of this end-user segment can be attributed to factors such as the high demand for end-to-end services in big pharmaceutical companies, rising pricing pressure and pipeline challenges in their operations (resulting in a shift toward contract development and manufacturing), and the growing need to streamline execution costs as a result of the patent expiry of blockbuster drugs.

The biologics manufacturing services segment will witness the highest growth in the pharmaceutical contract manufacturing market during the forecast period.

Based on service, the market is segmented into pharmaceutical manufacturing, biologics manufacturing, and drug development services. In 2020, the biologics manufacturing services segment accounted for the highest growth rate. The major factor driving the growth of this segment is the growing demand for vaccines and biosimilars.

Get 10% Free Customization on this Report:

The Asia Pacific region is the fastest-growing region of the pharmaceutical contract development and manufacturing market in 2020.

The Asia Pacific region is estimated to grow at the highest CAGR in the pharmaceutical contract development and manufacturing market during the forecast period, this is mainly due to factors such as increasing investments and

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain points around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 Micro Quadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Mr. Aashish Mehra
MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441


Research Insight:

Visit Our Website:

Content Source:

Related Report:–exclusive-report-by-marketsandmarkets-301394311.html